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ABSTRACT
Objective To assess the cost effectiveness of different
management strategies for urinary tract infections.
Design Cost effectiveness analysis alongside a
randomised controlled trial with a one month follow-up.
Setting Primary care.
Participants 309 non-pregnant adult women aged 18-70
presenting with suspected urinary tract infection.
Interventions Patients were randomised to five basic
management approaches: empirical antibiotics,
empirical delayed (by 48 hours) antibiotics, or targeted
antibiotics based on either a high symptom score (two or
more of urine cloudiness, smell, nocturia, dysuria),
dipstick results (nitrite or leucocytes and blood), or
receipt of a positive result on midstream urine analysis.
MainoutcomemeasureDurationofsymptomsandcostof
care.
Results Management with targeted antibiotics with
midstreamurineanalysiswas morecostlyovertheperiod
of one month. Costs for the midstream urine analysis and
dipstick management groups were £37 and £35,
respectively; these compared with £31 for immediate
antibiotics. Cost effectiveness acceptability curves
suggested that if avoiding a day of moderately bad
symptoms was valued at less than £10, then immediate
antibiotics is likely to be the most cost effective strategy.
For values over £10, targeted antibiotics with dipstick
testing becomes the most cost effective strategy, though
because of the uncertainty we can never be more than
70% certain that this strategy truly is the most cost
effective.
Conclusion Dipstick testing with targeted antibiotics is
likely to be cost effective if the value of saving a day of
moderately bad symptoms is £10 or more, but caution is
required given the considerable uncertainty surrounding
the estimates.
INTRODUCTION
Urinarytractinfectionsarecommoninfemalepatients
in general practice,
1 and urine is the most frequently
received specimen in microbiology laboratories.
These common bacterial infections affect half of all
women at least once in their lives.
2 Clinical manage-
ment strategies vary, with empirical antibiotics com-
monly used. Many practitioners, however, also use
urinary dipstick results and request analysis of mid-
stream urine samples. In over 62% of women present-
ingwithsuspectedurinarytractinfection,thediagnosis
islaboratoryconfirmed.
3Theuseofdipsticksandclin-
icalscoringalgorithmscanpotentiallyhelptoimprove
the precision of diagnosis by improving the positive
predictive values.
3 It is unclear what effects different
management strategies will have on the costs and cost
effectiveness. We carried out an economic evaluation
alongside a randomised controlled trial to investigate
thecostsandcosteffectivenessofthedifferentmanage-
ment strategies for urinary tract infection.
METHODS
Randomised controlled trial
General practitioners or practice nurses recruited
patients with suspected urinary tract infection, either
first time or recurrent, on presentation. The study
included 309 non-pregnant adult women aged 18-70.
The practitioner collected baseline symptoms, clinical
information, and demographic details. Patients com-
pleted a symptom diary for 14 days. Patients were ran-
domised to one of five management groups: empirical
antibiotictreatment;empiricaldelayedantibiotics;anti-
biotic targeted by symptom score; antibiotic according
to dipstick algorithm (nitrites or leucocytes and a trace
of blood); or midstream urine analysis with sympto-
matic treatment until culture and sensitivity results
were available and then antibiotics targeted accord-
ingly. Full details of this trial are given elsewhere.
4
Costs
Costs were estimated from an NHS perspective and
included the recruitmentconsultationwith the general
practitioner and all NHS contacts related to urinary
tract infection in a one month follow-up period. Costs
fortherecruitmentvisitincludedtheconsumablecosts
for midstream urine analysis and dipstick tests plus
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and laboratory costs were those of the local NHS
trust. The recruitment consultation was costed with
nationalunit costsper minutebased onthe durationof
consultation.
5 The time taken to explain and perform
the test was included within this consultation.
As we had no data on length of consultation for
39/309 patients (13%) and antibiotic use for 41/309
(13%), we imputed missing values using maximum
likelihood estimation for consultation time and a
regression method (with results constrained to be yes
or no) for antibiotic use (SPSS version 14). Original
data were checked to ensure that the means and stan-
dard errors of the estimates for the imputed variables
were equivalent (mean values within 1%) to those of
the originals. These two items were imputed as the
data relied on completion by the practitioner and we
had no a priori reason that it would be correlated with
patients’ characteristics and so would be unlikely to
bias results. Not imputing would have lost an addi-
tional 49 cases for the final analysis. For costing pur-
poses we assumed that antibiotics were prescribed
accordingtothestudyprotocol—thatis,trimethoprim,
costed as in the British National Formulary.
6 We
obtained details of use of resources during follow-up
directlyfromthepatient’sgeneralpracticenotes.Con-
tacts with general practitioners during follow-up were
costed as a standard 10 minute consultation.
5 Mid-
stream urine analysis and antibiotic use were recorded
andcostedwithmethodsdescribedearlier.Referralsto
secondarycareduringfollow-upwereincludedifthere
was a reasonable probability of the referral being attri-
butabletourinarytractinfections;thiswasdoneincon-
sultation with a clinical expert blind to management
strategy (PL). We used NHS reference costs.
7 All
costs were estimated for the year 2005-6 in pounds
(£). No time discounting was required.
Analysis
Using Microsoft Excel and SPSS version 14, we ana-
lysed the 83% (257/309) of participants for whom we
hadestimatesofbotheffectivenessandfollow-upcosts.
Theeconomicevaluationwasacosteffectivenessstudy
in terms of cost per day of moderate or severe
symptoms avoided. Symptom days were obtained
from the patient’s diary completed for the 14 days
after recruitment. To test the robustness of estimates
obtained we also estimated means using 1000 boot-
strap samples.
89 Bootstrapping was also used to esti-
mate cost effectiveness acceptability curves (CEAC)
for the cost per day of moderate or severe symptoms
avoided.
10
Scenario analysis
To investigate the potential cost per QALY of different
management strategies a scenario analysis used a utility
loss of 0.2894 for a day with urinary tract infection
symptoms.
11 We also carried out a threshold analysis
to show the utility loss per day of symptoms required
to produce a cost per QALY ratio of between £20000
and£30000,thevaluesusedinNICE(NationalInstitute
for Health and Clinical Excellence) decision making.
12
RESULTS
Theresourcesusedbypatientsinthefivemanagement
groups varied as expected (table 1), with those in the
dipstick group requiring the longest consultation and
those in the empirical antibiotics group the shortest.
The frequency of antibiotic use and investigations
also varied as expected between management groups,
as did the costs at one month (range £30.70-£37.10)
(table 2). These costs were attributable mainly to the
initial consultation.
Management strategies were ranked by mean effec-
tiveness (table 3); differences between groups were
small. Three strategies were dominated (delayed anti-
biotics, symptom score, and midstream urine), mean-
ing some other strategy was both less costly and more
effective. The immediate antibiotics and dipstick
groups were not dominated and incremental results
are given for the dipstick group compared with the
immediate antibiotic group. Although no effect differ-
encesweresignificantinconventional(frequentist)sta-
tistics, current health economic practices combine
such data in cost effectiveness acceptability curves.
Cost effectiveness acceptability curves by strategy
(figure) indicate that if avoiding a day of symptoms is
valued at less than £10, the most cost effective strategy
Table 1 |Resource use by patients* with urinary tract infection according to allocation to management strategy group
Immediate antibiotics
(n=56)
Midstream urine
(n=46)
Dipstick
(n=42)
Symptom scores
(n=60)
Delayed antibiotics
(n=53)
Recruitment visit to general practice
Mean length (mins) 11.6 12.4 13.0 11.9 12.5
Midstream urine samples taken 15 40 16 20 8
Dipstick tests carried out 31 22 40 35 17
No (%) prescribed antibiotics 54 (96) 38 (83) 32 (76) 52 (87) 40 (75)
Reconsultations with general practitioner within 1 month
No of visits 6 9 6 8 6
Midstream urine sample taken 3 3 4 5 3
Prescribed antibiotics 4 7 5 7 5
Referred to secondary care 0 0 0 0 0
*Excluding 52 who did not have complete follow-up data
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£10, the dipstick strategy becomes the most cost effec-
tive, although given the uncertainty present we can
only ever be 70% certain that this strategy really is the
most cost effective. The scenario analysis produced an
incremental cost per QALY ratio of £12100 for the
dipstick test compared with immediate antibiotics.
Threshold analysis indicated that a utility loss per day
of symptoms of between 0.117 and 0.175 produced a
cost per QALY of between £20000 and £30000.
DISCUSSION
All management strategies for urinary tract infection
have similar resource implications. The similarities in
cost are not surprising as the tests used in this study
have low costs and would entail only small changes to
the time practitioners would need to providecare for a
patientwithaurinarytractinfection.Thereforethereis
no strong reason to prefer any particular management
strategy on the basis of costs. The duration of symp-
toms was similar between groups, with the dipstick
strategy being associated with the shortest duration of
symptoms.Comparedwiththegroupgivenimmediate
antibiotics,thedipstickstrategycost£10peradditional
day of symptoms avoided.
Strengths and limitations
Thecurrentstudyisbasedonarandomisedcontrolled
trial with a rigorously developed dipstick algorithm
and clinical score. The studied group comprised
women in whom urinary tract infection was the sus-
pected diagnosis.
13 They had similar characteristics to
national attending samples in the United Kingdom
1 so
study results should be representative of routine clini-
calpractice.Dataonresourcewasobtainedfromstudy
records or from general practitioners’ notes.
The cost effectiveness analysis shown here presents
estimates of the cost per day of symptoms avoided.
These results should be interpreted with caution
because of the lack of significance in the effectiveness
data.
4 It is unclear why there were better outcomes in
the dipstick group than in the immediate group as use
ofantibioticswashigherintheimmediategroup(96%v
76%). Those in the dipstick group, however, had less
severe symptoms.
4 The improvement in the dipstick
group could be related to the security of feeling that
they know from dipsticks that they do or do not have
an infection.
We considered only costs related to the NHS; this
might miss important costs such as travel and time off
work, which might be relevant as 83% of the partici-
pants were aged under 60. We had details on time off
workorstudyfor146/257womenandofthese48/146
(33%)neededtimeoffbecauseoftheirinfection.There
were no significant differences, however, between any
of the groups so it is unlikely that considering these
costs would have altered the results. Some additional
travel costs would have been associated with reconsul-
tations but these were low, with an average of 0.13
reconsultations during follow-up.
Our analysis excluded any benefits associated with
reducing the use of antibiotics, such as less antibiotic
resistance. Strategies that reduce use of antibiotics are
thus undervalued.
14 The highest numbers prescribed
antibiotics were in the group prescribed immediate
antibiotics (table 1).
Table 2 |Mean (SD) costs (£) and effectiveness of management strategies for urinary tract infection
Immediate antibiotics Midstream urine Dipstick Symptom scores Delayed antibiotics
Recruitment visit:
General practice visit 25.5 (8.7) 27.3 (11) 28.6 (9.5) 26.2 (10.3) 27.4 (10.8)
Midstream urine 1.2 (1.9) 3.8 (1.5) 1.7 (2.1) 1.4 (2.1) 0.7 (1.6)
Dipstick 0.2 (0.2) 0.2 (0.2) 0.4 (0.1) 0.3 (0.2) 0.1 (0.2)
Antibiotics 1.0 (0.2) 0.8 (0.4) 0.8 (0.4) 0.9 (0.3) 0.7 (0.4)
Total 27.8 (9.1) 32.1 (11.1) 31.4 (9.8) 28.7 (10.2) 29.0 (11.2)
Follow-up at 1 month:
General practice visit 2.4 (6.9) 4.3 (8.8) 3.1 (9.2) 2.9 (8.6) 2.5 (8.3)
Midstream urine 0.2 (1) 0.3 (1.1) 0.4 (1.3) 0.4 (1.2) 0.2 (1)
Referred to secondary care 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Antibiotics 0.2 (0.9) 0.4 (1.4) 0.3 (1) 0.2 (0.8) 0.1 (0.4)
Total 2.8 (8.2) 5.0 (10.4) 3.9 (11) 3.5 (10.2) 2.9 (9.5)
Total cost in 1st month 30.6 (13.9) 37.1 (15) 35.3 (13.3) 32.3 (13.9) 31.9 (15.8)
Effectiveness (days of
moderate/severe symptoms)
3.63 (2.7) 4.17 (3.1) 3.14 (2.1) 3.92 (3.6) 3.92 (3.8)
Value of moderate/severe symptom days avoided (£)
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There is limited evidence on the cost effectiveness of
differentmanagementstrategiesforurinarytractinfec-
tion in primary care. Three studies used modelling to
examine similar questions. The literature identified is
either from the United States or the UK and hence the
values presented here use different currency unit and
costyears.Toaidcomparisonwealsopresentvaluesin
2005-6£usingUK
15orUS
16inflationindicatorsandan
exchange rate of $1.78 to the £
17; adjusted values are
giveninbrackets.Allthe studiesfound thatimmediate
(empirical) antibiotics were the least costly. A UK
based study of management of urinary tract infection
in general practice found that laboratory testing with
empirical antibiotics resulted in earlier resolution of
symptomsatacostof£215(£246)perdayofsymptoms
avoided compared with empirical antibiotics.
18 AU S
cost utility study found that compared with empirical
treatment a complete urinalysis cost $2964 per addi-
tional QALM (quality adjusted life month) and dip-
sticks cost $48460 per QALM (equivalent to £25682
and £419894 per QALY, respectively).
11 A further
study found that treatment for urinary tract infection
with accompanying over-the-counter dipstick test
cost between $5.50 and $1.97 (£4.14 and £1.48) per
dayofsymptomsavoided,dependingonhoweffective
the dipstick was in directing treatment to those who
actually had a urinary tract infection.
14 These results
are consistent with those presented here as they show
that tests can be associated with additional costs and
additional days of symptoms avoided.
Interpretation of results
Ouranalysissuggeststhateachadditionaldayofsymp-
tomscanbeavoidedatacostofabout£10.Ajudgment
would therefore need to be made of whether the value
of avoiding days of moderate or severe symptoms
would exceed this. The scenario analysis we con-
structed suggested that if a day of symptoms was asso-
ciated with a utility loss of 0.2984 then the dipstick
strategy could generate extra QALYs at a cost per
QALYofaround£12000.Thisanalysisshouldbetrea-
ted with caution, however, as the estimate of 0.2984
was not derived directly from patients. More informa-
tiononutilitylossesassociatedwithurinarytractinfec-
tion symptomswould be importantin determiningthe
value of days of symptoms avoided and hence in
informing the care of affected patients.
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